Identification and characterization of anti-prionic compounds that disassemble Tau prions as a novel therapeutic approach for tauopathies
Objective: Stabilization of monomeric Tau protein by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for tauopathies. Background: Tauopathies…Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…Refractory tremor: is perampanel a potentially useful therapy?
Objective: To describe our series of patients with refractory tremor eventually treated with perampanel and to analyse its clinical outcomes. Background: Up to 40% of…Influencing factors when living with Parkinson’s disease: beyond the disease symptomatology
Objective: To identify which are the factors that influence in the process of living with Parkinson's disease (PD). Background: Living with PD is a complex,…On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…Effect of opicapone and entacapone on levodopa short duration response
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy and safety of CX-8998 in T-CALM, a randomized, double-blind, placebo-controlled, phase 2a trial in participants with essential tremor: subgroup analysis by baseline tremor severity
Objective: Evaluate efficacy and safety of CX-8998 in essential tremor (ET) as a function of baseline tremor severity. Background: CX-8998, a selective modulator of T-type…Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France
Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)
Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 34
- Next Page »